Navigation Links
Lexicon Announces Pricing of Common Stock in Public Offering
Date:3/16/2010

THE WOODLANDS, Texas, March 16 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of a public offering and concurrent private placement of its common stock in which  the aggregate net proceeds to Lexicon will be approximately $165.0 million.  The public offering consists of 87,717,391 shares of its common stock at a public offering price of $1.15 per share.  In connection with the public offering, Lexicon agreed to sell an additional 59,296,749 shares of its common stock at the public offering price to Invus, L.P., Lexicon's largest stockholder, in a concurrent private placement upon Invus' exercise of its right to purchase shares sufficient to maintain its pro rata ownership of Lexicon's common stock.

All of the shares subject to the public offering are being offered by Lexicon pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.  Lexicon has also granted the underwriters a 30-day option to purchase up to an aggregate of 8,804,348 additional shares of common stock to cover over-allotments, if any.  To the extent the underwriters exercise their over-allotment option, Invus may purchase up to an aggregate of 5,951,718 additional shares of common stock in a private placement pursuant to its right to purchase shares sufficient to maintain its pro rata ownership of Lexicon's common stock.  Morgan Stanley & Co. Incorporated and J.P. Morgan Securities Inc. are ac
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
2. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
3. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
5. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
6. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
7. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
8. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
9. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
10. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... -- The element of surprise has been a major advantage ... warning. Until now, epidemiologists had nothing to measure that ... in suboptimal responses to both the H1N1 pandemic of ... - http://photos.prnewswire.com/prnh/20141121/160242 That virus ... gene structural changes have been found that invariably to ...
(Date:11/21/2014)... TRU-D SmartUVC LLC and its UK partners, Rapid Disinfection ... TRU-D SmartUVC, at FIS 2014 in Harrogate, England ... Stand 23. The conference, hosted by Federation of ... largest infection-related event of its kind and brings together more ... events of its type throughout the world. This annual event ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” ... was an “Award-Winning Finalist in the “Fiction: Short Story” ... . , Jeffrey Keen, President and CEO of USA ... entries from mainstream and independent publishers, including Simon & ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... The 14th Annual National Ergonomics,Conference and Exposition (NECE) ... a record number of conference sessions, and mark ... geared toward workplace design,and occupational health professionals, as ... environments. These new tracks are coupled with,the NECE,s ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, today announced that its Senior Vice,President and ... a,company overview at the upcoming CIBC World Markets ... 2008 at 3:25 pm (eastern,time), at the Centre ...
... Shandong, China, Sept. 17 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... Biologic",or the "Company"), one of the leading ... China ("PRC"), today announced that the Company,received ... Drug Administration (the,"SFDA") to commence clinical trial ...
Cached Biology Technology:2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expo's 14-Year History 22008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expo's 14-Year History 3China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... London, New Delhi, Singapore and Washington DC (July 27, ... of Medical Decision Making , a large-scale, covert ... resources even with an extremely effective public health response, ... and initiating a response to it. The article ...
... 2009) An Italian research team, publishing in the ... is now available on-line without charge at http://www.ingentaconnect.com/content/cog/ct ... placenta may ultimately play a role in the treatment ... diseases caused by tuberculosis, chemical exposure, radiation or pathogens. ...
... Royal Holloway, University of London, has discovered evidence that ... frogs. The research, published in the August edition of ... about our long-tongued friends: wild frogs in the UK ... conducted her research with colleagues from the Institute of ...
Cached Biology News:Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2Placenta-derived stem cells may help sufferers of lung diseases 2Disease threat may change how frogs mate 2